Genetic Testing and Counselling in Breast Cancer: Practice-based data from an Italian Tertiary Centre
Abstract
Background: Integration of germline genetic testing with clinical genetic counselling is essential to guide prevention, surveillance, and personalised treatment in breast cancer. However, real-world implementation and access remain variable. We evaluated the impact of a structured genetic programme in a tertiary referral centre.
Methods: This retrospective study included patients with breast cancer undergoing germline testing and genetic counselling between January 2019 and July 2025 at the San Camillo-Forlanini Hospital (Rome), a referral hub for multiple oncology centres. Testing included BRCA1/2 (NGS/MLPA) and multigene panels, with variants classified per ACMG/AMP criteria. Clinical and treatment data were integrated with genetic findings.
Results: Among 4,573 patients, 325 carried pathogenic/likely pathogenic variants (7.1%, 95% CI: 6.4–7.9), mainly BRCA2 (37.0%) and BRCA1 (32.0%);87% were high/moderate-penetrance genes. Multigene testing increased detection of less common variants. Median age at diagnosis was 45 years. Uptake of preventive surgery was substantial, although variability persisted. Use of targeted therapies (e.g. PARP inhibitors) was inconsistent.Genetic counselling identified high-risk individuals eligible for intensified surveillance and risk-reducing strategies, including prophylactic bilateral mastectomy and salpingo-oophorectomy. Among carriers of high-risk variants, 86.4% underwent prophylactic or therapeutic mastectomy, reaching 94.1% in BRCA1 carriers. Five-year overall survival was 94%.
Conclusions: Integrated genetic testing and counselling support the implementation of effective prevention strategies in hereditary breast cancer, extending their impact beyond affected patients to unaffected relatives through cascade testing. However, gaps remain in equitable access and consistent application of personalised interventions. Strengthening coordinated, population-based genetic services is essential to maximise public health impact.
Key messages: • Systematic germline testing with counselling identifies a relevant proportion of hereditary breast cancer, enabling prevention strategies, organ-specific surveillance, and target treatments.
• Integrated services with cascade testing may ensure equitable access, reduce costs and duplication, and provide more standardised yet personalised care across centres, enhancing public health impact.
Related
- Partial Trisomy 20qter on a Derivative Chromosome 22 in a Northern Italian Genetic Isolate with Oculo-Auriculo-Vertebral Spectrum-Related Features
- Genetic dissection of a Solanum elaeagnifolium tertiary genepool introgression associated with 4-O-caffeoylquinic acid accumulation in eggplant
- Toward Increasing Cost‐Effectiveness of Genetic Testing in Movement Disorders
- Genetic testing in pituitary adenomas: a Pituitary Society International Consensus Statement
- To Test or Not to Test: A Real‐World Study of Employee Views and Decision‐Making for Genetic Testing in the Workplace
BibTeX
@article{dajko2026genetic,
title = {{Genetic Testing and Counselling in Breast Cancer: Practice-based data from an Italian Tertiary Centre}},
author = {M Dajko and V Rossi and D Di Giacomo and S Grotta and Ch Lolli and C De Bernardo and NMR Pignataro and G D’Auria and P Grammatico and M Valiante},
journal = {The European Journal of Public Health},
year = {2026},
month = oct,
doi = {10.1093/eurpub/ckag169.1852},
url = {https://doi.org/10.1093/eurpub/ckag169.1852},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Genetic Testing and Counselling in Breast Cancer: Practice-based data from an Italian Tertiary Centre
AU - M Dajko
AU - V Rossi
AU - D Di Giacomo
AU - S Grotta
AU - Ch Lolli
AU - C De Bernardo
AU - NMR Pignataro
AU - G D’Auria
AU - P Grammatico
AU - M Valiante
PY - 2026
DA - 2026/10/01
JO - The European Journal of Public Health
DO - 10.1093/eurpub/ckag169.1852
UR - https://doi.org/10.1093/eurpub/ckag169.1852
AB - Background: Integration of germline genetic testing with clinical genetic counselling is essential to guide prevention, surveillance, and personalised treatment in breast cancer. However, real-world implementation and access remain variable. We evaluated the impact of a structured genetic programme in a tertiary referral centre. Methods: This retrospective study included patients with breast cancer undergoing germline testing and genetic counselling between January 2019 and July 2025 at the San Camillo-Forlanini Hospital (Rome), a referral hub for multiple oncology centres. Testing included BRCA1/2 (NGS/MLPA) and multigene panels, with variants classified per ACMG/AMP criteria. Clinical and treatment data were integrated with genetic findings. Results: Among 4,573 patients, 325 carried pathogenic/likely pathogenic variants (7.1%, 95% CI: 6.4–7.9), mainly BRCA2 (37.0%) and BRCA1 (32.0%);87% were high/moderate-penetrance genes. Multigene testing increased detection of less common variants. Median age at diagnosis was 45 years. Uptake of preventive surgery was substantial, although variability persisted. Use of targeted therapies (e.g. PARP inhibitors) was inconsistent.Genetic counselling identified high-risk individuals eligible for intensified surveillance and risk-reducing strategies, including prophylactic bilateral mastectomy and salpingo-oophorectomy. Among carriers of high-risk variants, 86.4% underwent prophylactic or therapeutic mastectomy, reaching 94.1% in BRCA1 carriers. Five-year overall survival was 94%. Conclusions: Integrated genetic testing and counselling support the implementation of effective prevention strategies in hereditary breast cancer, extending their impact beyond affected patients to unaffected relatives through cascade testing. However, gaps remain in equitable access and consistent application of personalised interventions. Strengthening coordinated, population-based genetic services is essential to maximise public health impact. Key messages: • Systematic germline testing with counselling identifies a relevant proportion of hereditary breast cancer, enabling prevention strategies, organ-specific surveillance, and target treatments. • Integrated services with cascade testing may ensure equitable access, reduce costs and duplication, and provide more standardised yet personalised care across centres, enhancing public health impact.
SN - 1101-1262
SN - 1464-360X
ER -